High IL‐6 content in peripheral blood in patients with advanced non‐small cell lung cancer may contribute to poor anti‐PD‐1 efficacy and short duration of PFS through inducing alterations in the tumor microenvironment. This evidence concerns the gene PDCD1 and lung cancer.